WO2000061126A3 - Method of treating neurological disorders with combinations of nitric oxide synthase inhibitors and excitatory amino acid receptor modulators - Google Patents

Method of treating neurological disorders with combinations of nitric oxide synthase inhibitors and excitatory amino acid receptor modulators Download PDF

Info

Publication number
WO2000061126A3
WO2000061126A3 PCT/GB2000/001284 GB0001284W WO0061126A3 WO 2000061126 A3 WO2000061126 A3 WO 2000061126A3 GB 0001284 W GB0001284 W GB 0001284W WO 0061126 A3 WO0061126 A3 WO 0061126A3
Authority
WO
WIPO (PCT)
Prior art keywords
nitric oxide
oxide synthase
combinations
amino acid
excitatory amino
Prior art date
Application number
PCT/GB2000/001284
Other languages
French (fr)
Other versions
WO2000061126A2 (en
Inventor
Michael John O'neill
Original Assignee
Lilly Co Eli
Michael John O'neill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Michael John O'neill filed Critical Lilly Co Eli
Priority to AU39777/00A priority Critical patent/AU3977700A/en
Publication of WO2000061126A2 publication Critical patent/WO2000061126A2/en
Publication of WO2000061126A3 publication Critical patent/WO2000061126A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a method of treating a neurological disorder comprising administering to a patient an effective amount of a nitric oxide synthase inhibitor in combination with an effective amount of an excitatory amino receptor modulator.
PCT/GB2000/001284 1999-04-09 2000-04-06 Method of treating neurological disorders with combinations of nitric oxide synthase inhibitors and excitatory amino acid receptor modulators WO2000061126A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU39777/00A AU3977700A (en) 1999-04-09 2000-04-06 Method of treating neurological disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9908175.4A GB9908175D0 (en) 1999-04-09 1999-04-09 Method of treating neurological disorders
GB9908175.4 1999-04-09

Publications (2)

Publication Number Publication Date
WO2000061126A2 WO2000061126A2 (en) 2000-10-19
WO2000061126A3 true WO2000061126A3 (en) 2001-08-23

Family

ID=10851263

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/001284 WO2000061126A2 (en) 1999-04-09 2000-04-06 Method of treating neurological disorders with combinations of nitric oxide synthase inhibitors and excitatory amino acid receptor modulators

Country Status (3)

Country Link
AU (1) AU3977700A (en)
GB (1) GB9908175D0 (en)
WO (1) WO2000061126A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8841323B2 (en) 2006-03-15 2014-09-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8906939B2 (en) 2007-03-07 2014-12-09 Janssen Pharmaceuticals, Inc. 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9085577B2 (en) 2009-05-12 2015-07-21 Janssen Pharmaceuticals, Inc. 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1484642A (en) * 2001-01-05 2004-03-24 Excitatory amino acid receptor antagonists
US20040138204A1 (en) * 2002-10-30 2004-07-15 Harrington James Frederick Compositions and methods for pain reduction
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
EP2338492A1 (en) * 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
KR102502485B1 (en) 2014-01-21 2023-02-21 얀센 파마슈티카 엔.브이. Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
UA121965C2 (en) 2014-01-21 2020-08-25 Янссен Фармацевтика Нв Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005775A1 (en) * 1991-09-13 1993-04-01 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase
WO1994006428A1 (en) * 1992-09-22 1994-03-31 The Children's Medical Center Corporation Method of preventing nmda receptor complex-mediated neuronal damage
WO1995002602A1 (en) * 1993-07-16 1995-01-26 Rhone-Poulenc Rorer S.A. Imidazo(1,2-a)pyrazin-4-one derivatives for use as ampa and nmda receptor antagonists
WO1996021445A1 (en) * 1995-01-13 1996-07-18 The General Hospital Corporation Methods of inhibiting neurodegenerative diseases
US5614508A (en) * 1995-06-07 1997-03-25 Warner-Lambert Company Amino acid derivatives of substituted quinoxaline 2,3-dione derivatives as glutamate receptor antagonists
WO1997018805A1 (en) * 1995-11-21 1997-05-29 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers
WO1997032585A1 (en) * 1996-03-05 1997-09-12 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
WO1998023609A1 (en) * 1996-11-25 1998-06-04 The Procter & Gamble Company 2-imidazolinylaminoindazole compounds useful as alpha-2 adrenoceptor agonists
WO1999008669A1 (en) * 1997-08-15 1999-02-25 Carolyn Ann Fairbanks Agmatine as a treatment for neuropathic pain
WO1999037768A1 (en) * 1998-01-22 1999-07-29 The Johns Hopkins University Capon: a protein associated with neuronal nitric oxide synthase

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005775A1 (en) * 1991-09-13 1993-04-01 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase
WO1994006428A1 (en) * 1992-09-22 1994-03-31 The Children's Medical Center Corporation Method of preventing nmda receptor complex-mediated neuronal damage
WO1995002602A1 (en) * 1993-07-16 1995-01-26 Rhone-Poulenc Rorer S.A. Imidazo(1,2-a)pyrazin-4-one derivatives for use as ampa and nmda receptor antagonists
WO1996021445A1 (en) * 1995-01-13 1996-07-18 The General Hospital Corporation Methods of inhibiting neurodegenerative diseases
US5614508A (en) * 1995-06-07 1997-03-25 Warner-Lambert Company Amino acid derivatives of substituted quinoxaline 2,3-dione derivatives as glutamate receptor antagonists
WO1997018805A1 (en) * 1995-11-21 1997-05-29 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers
WO1997032585A1 (en) * 1996-03-05 1997-09-12 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
WO1998023609A1 (en) * 1996-11-25 1998-06-04 The Procter & Gamble Company 2-imidazolinylaminoindazole compounds useful as alpha-2 adrenoceptor agonists
WO1999008669A1 (en) * 1997-08-15 1999-02-25 Carolyn Ann Fairbanks Agmatine as a treatment for neuropathic pain
WO1999037768A1 (en) * 1998-01-22 1999-07-29 The Johns Hopkins University Capon: a protein associated with neuronal nitric oxide synthase

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BHARDWAJ ET AL: "Characterization of metabotropic glutamate receptor-mediated nitric oxide production in vivo", J. CEREB. BLOOD FLOW METAB., vol. 17, no. 2, 1997, pages 153 - 160, XP000987201 *
GORBUNOV ET AL: "Activation of glutamate receptors stimulates the formation of nitrite in", J. NEUROCHEM., vol. 62, no. 6, 1994, pages 2205 - 2211, XP000987092 *
HICKS ET AL: "Evaluation of glycine site antagonists of the NMDA receptor in global cerebral ischemia", BRAIN RESEARCH, vol. 819, no. 1,2, 1999, pages 65 - 74, XP000952570 *
HICKS, C. A. ET AL: "Synergistic neuroprotective effects by combining an NMDA or AMPA receptor antagonist with nitric oxide synthase inhibitors in global cerebral ischemia", EUR. J. PHARMACOL. (1999), 381(2/3), 113-119, XP000952157 *
MONTECOT ET AL: "Inhibition of neuronal (type 1) nitric oxide synthase prevents hyperemia and hippocampal lesions resulting from kainate-induced seizures", NEUROSCIENCE, vol. 84, no. 3, 1998, pages 791 - 800, XP000984169 *
O'NEILL, M J ET AL: "Neuroprotective effects of 7- nitroindazole in the gerbil model of global cerebral ischemia", EUR. J. PHARMACOL. (1996), 310(2/3), 115-122, XP000920693 *
TUTKA ET AL: "NG-nitro-L-arginine differentially affects glutamate- or kainate-induced seizures", NEUROREPORT, vol. 7, no. 10, 1996, pages 1605 - 1608, XP000987090 *
YAMADA ET AL: "Two pathways of nitric oxide production through glutamate receptors in the rat", NEUROSCI. RES., vol. 98, no. 2, 1997, pages 93 - 102, XP000984193 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266834B2 (en) 2006-03-15 2016-02-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8841323B2 (en) 2006-03-15 2014-09-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8906939B2 (en) 2007-03-07 2014-12-09 Janssen Pharmaceuticals, Inc. 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
US9132122B2 (en) 2007-09-14 2015-09-15 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9085577B2 (en) 2009-05-12 2015-07-21 Janssen Pharmaceuticals, Inc. 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9226930B2 (en) 2009-05-12 2016-01-05 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors

Also Published As

Publication number Publication date
WO2000061126A2 (en) 2000-10-19
AU3977700A (en) 2000-11-14
GB9908175D0 (en) 1999-06-02

Similar Documents

Publication Publication Date Title
WO2000061126A3 (en) Method of treating neurological disorders with combinations of nitric oxide synthase inhibitors and excitatory amino acid receptor modulators
CA2222303A1 (en) Use of at least one no synthase inhibitor for treating sensitive skin
WO2004019863A3 (en) Combination therapy for treatment of fibrotic disorders
IL134164A (en) Gaba analogs to prevent and treat gastrointestinal damage and disorders
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
WO2000038730A3 (en) Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
WO2000061192A3 (en) Methods and compositions for the treatment of pancreatitis
WO2002005791A3 (en) Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor
WO2005030118A3 (en) Targeted release of nitric oxide in the cns circulation for modulating the bbb and treating disorders
WO2003032912A3 (en) Treatment of cns disorders using cns target modulators
WO2001068096A3 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
WO2002084298A3 (en) Medicaments which are modulators of hm74 and/or hm74a activity
EP1534862A4 (en) Modulators of rabggt and methods of use thereof
HU0003863D0 (en) Alpha-sulfonylamino hidroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders
HUP0004025A3 (en) Treatment of conduct disorder using norepinephrine reuptake inhibitors
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
WO2002015920A3 (en) Treatment of hyperproliferative diseases
WO2002051434A3 (en) Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders
WO2000033814A3 (en) Method for administering agents to the central nervous system
WO2004046309A3 (en) Methods for inhibiting viral replication in vivo
EP1099442A3 (en) Methods of administering apo B-secretion/MTP inhibitors
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
WO1998018440A3 (en) Use of inhibitors of the activity of retinoic acid for treating sensitive skin
WO2002062327A3 (en) Method of treating neurological disorders using acetone derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP